Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Safe Use workshop set

This article was originally published in The Tan Sheet

Executive Summary

FDA officials discuss the status of Safe Use Initiative activities and future projects at a public workshop in November. According to the agency's website, FDA will gather input and perspectives for directions toward the development of "collaborative, cross-sector safe medication use activities with healthcare stakeholders." FDA scheduled the meeting for Nov. 16, 8:30 a.m. to 4:45 p.m. EST, and Nov. 17, 8:30 a.m. to 12 p.m., in Silver Spring, Md. FDA launched the initiative in 2008 to reduce the likelihood of preventable injury and death caused by medical errors, unintentional exposure to drugs, misuse, abuse or attempts at self-harm (1"The Tan Sheet" May 10, 2010)


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts